Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Cancer Drug Development”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Cancer Drug Development”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at [email protected]. We look forward to working with you in the future.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Cancer Metastasis”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Cancer Metastasis”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at [email protected]. We look forward to working with you in the future.

A range of MDPI journals will be attending the 15th Annual Meeting of Chinese Society for Immunology. This meeting will be held in Chongqing, China, from 27 to 30 December 2022.

The conference focuses on the following areas:

• Recognition and regulation of innate immune responses;
• Adaptive immune response;
• Immune metabolism and immune regulation;
• Immunity to COVID-19 infection;
• Tumor immunity and tumor immunotherapy;
• Autoimmune diseases and other topics.

The following MDPI journals will be represented:

• IJMS (leading journal);
• Vaccines;
• Metabolites;
• Cells;
• Cancers;
• Biomedicines;
• CIMB;
• Pathogens;
• Immuno.

If you plan on attending this conference, feel free to stop by our booth #B13. Our delegates look forward to meeting you in person to answer any questions you may have.

For more information about the conference, please see the following link: https://csimeeting2022.sciconf.cn/cn/web/index/13562.  

Lung cancer is the most common malignancy in many parts of the world. It is often diagnosed late and has one of the poorest outcomes among other cancers. Recent studies (NELSON from Europe and NLST from USA) have shown that lung cancer screening via computed tomography scans can identify lung cancer at an earlier stage in certain populations, and reduce mortality. The diagnosis and management of these tumors, with many being small nodules or ground glass changes, remain a challenge. The landscape and management of lung cancer in general have also changed dramatically in the last decade, perhaps more than any other thoracic disease. Advances in surgery and cancer genetics facilitate personalized drug therapies that can provide ever more complex and innovative treatment algorithms to fight this terrible disease. The role of liquid biopsies, more targeted bespoke drug therapies, non-invasive endoscopic treatments, and high-precision surgeries are only some of the evolving horizons in lung cancer management.

November 2022 is designated as "World Lung Cancer Awareness Month", with various global activities that highlight and increase awareness of lung cancer for research support and development. We would like to share some of the high-quality and innovative research findings published in Cancers (ISSN: 2072-6694).

The list of relevant papers can be seen below:

“The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells”
by Dong Young Kang, Nipin Sp, Eun Seong Jo, Alexis Rugamba, Dae Young Hong, Hong Ghi Lee, Ji-Seung Yoo, Qing Liu, Kyoung-Jin Jang and Young Mok Yang
Available online: https://www.mdpi.com/2072-6694/12/3/727

“Extracellular Vesicle lincRNA-p21 Expression in Tumor-Draining Pulmonary Vein Defines Prognosis in NSCLC and Modulates Endothelial Cell Behavior”
by Joan J. Castellano, Ramon M. Marrades, Laureano Molins, Nuria Viñolas, Jorge Moises, Jordi Canals, Bing Han, Yan Li, Daniel Martinez, Mariano Monzó et al.
Available online: https://www.mdpi.com/2072-6694/12/3/734

“Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient”
by Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco et al.
Available online: https://www.mdpi.com/2072-6694/12/5/1125

“¹⁸F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival”
by Giulia Polverari, Francesco Ceci, Valentina Bertaglia, Maria Lucia Reale, Osvaldo Rampado, Elena Gallio, Roberto Passera, Virginia Liberini, Paola Scapoli, Vincenzo Arena et al.
Available online: https://www.mdpi.com/2072-6694/12/5/1163

“Association of a CT-Based Clinical and Radiomics Score of Non-Small Cell Lung Cancer (NSCLC) with Lymph Node Status and Overall Survival”
by Francesca Botta, Sara Raimondi, Lisa Rinaldi, Federica Bellerba, Federica Corso, Vincenzo Bagnardi, Daniela Origgi, Rocco Minelli, Giovanna Pitoni, Francesco Petrella et al.
Available online: https://www.mdpi.com/2072-6694/12/6/1432

“Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab”
by Romain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, Marie-Ange Massiani, Michael Soussan, Gérald Bonardel, Christos Chouaid, Margot Playe, Lucas Goldfarb, Boris Duchemann et al.
Available online: https://www.mdpi.com/2072-6694/12/8/2234

“Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study”
by Pierre-Jean Lamy, Paul van der Leest, Nicolas Lozano, Catherine Becht, Frédérique Duboeuf, Harry J. M. Groen, Werner Hilgers, Nicolas Pourel, Naomi Rifaela, Ed Schuuring et al.
Available online: https://www.mdpi.com/2072-6694/12/10/3002

“Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies”
by Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow and Giandomenico Roviello
Available online: https://www.mdpi.com/2072-6694/12/11/3293

“A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC”
by Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson and Bilal Piperdi
Available online: https://www.mdpi.com/2072-6694/12/12/3648

“Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review”
by Alice Indini, Erika Rijavec and Francesco Grossi
Available online: https://www.mdpi.com/2072-6694/13/8/1794

You are welcome to submit relevant papers to the Special Issue “World Lung Cancer Awareness Month”.

Dr. Calvin Sze Hang Ng
Editorial Board Member of Cancers

Stanford University has recently published an update of the list of the top 2% most widely cited scientists. The time node of the statistical data of this list is from 1960 to 2022, and it is divided into two lists: "Lifetime Scientific Influence Ranking" and "2022 Annual Scientific Influence Ranking". The "Lifetime Scientific Influence Ranking" counts the comprehensive influence performance of scientists during their careers, and the "2022 Annual Influence Ranking" focuses on highlighting the academic influence of scientists in the previous year. This ranking, considered the most prestigious worldwide, is based on the bibliometric information contained in the Scopus database and includes more than 200,000 researchers from the more than 10 million scientists considered to be active worldwide, with 22 scientific fields and 176 subfields taken into account.

We are pleased to share that 670 Editorial Board Members from MDPI’s Cancers (ISSN: 2072-6694) were featured in Stanford University World’s Top 2% Scientists list in 2022.

The latest Stanford rankings reflect the significant influence and research excellence of the scientists, who are committed to furthering their knowledge for the benefit of the world.

We would like to congratulate our Editorial Board Members on their excellent achievement and thank them for their immense contribution to the scientific progression and development of Cancers. 

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Pediatric Oncology”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Pediatric Oncology”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at [email protected]. We look forward to working with you in the future.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Cancer Informatics and Big Data”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Cancer Informatics and Big Data”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at [email protected]. We look forward to working with you in the future.

MDPI will be attending the 27th Congress of the Chinese Pediatric Society, held in Changsha, China, from 15–18 December 2022.

The following MDPI journals will be represented:

• Children (leading journal);
• JPM;
• Medicina;
• Audiology Research;
• JCM;
• Healthcare;
• Diagnostics;
• Metabolites;
• Cancers;
• Nutrients. 

If you plan on attending this conference, feel free to stop by our booth: #B67. Our delegates look forward to meeting you in person to answer any questions that you may have. 

For more information about the conference, please see the following link: https://nccps2022.tiemeeting.com/CN.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Infectious Agents and Cancer”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Infectious Agents and Cancer”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at [email protected]. We look forward to working with you in the future.

MDPI is pleased to announce the publication of the inaugural issues of eight new Open Access journals. We wish to thank all the Editors-in-Chief, Associate Editors, and Editorial Board Members involved who will be shaping the future course of these brand-new journals.

The new titles presented below were set up as a result of our market research, which showed there is a need for Gold Open Access journals in each of these areas of research. At MDPI, the same trusted, fast, and rigorous peer-review process is employed across journals and disciplines.

MDPI is committed to promoting diverse open science exchanges and provides support to academic organizations and institutions willing to join the open access publishing model.

If you are interested in jointly creating more open access journals with us to publish cutting-edge research, please send your journal proposal application here, and please do not hesitate to contact us ([email protected]) for further details.

1. “Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis”
by Usman, S.; Waseem, N. H.; Nguyen, T. K. N.; Mohsin, S.; Jamal, A.; Teh, M.-T. and Waseem, A.
Cancers 2021, 13(19), 4985; https://doi.org/10.3390/cancers13194985
Available online: https://www.mdpi.com/2072-6694/13/19/4985

2. “Prognostic Utility of Platelet–Lymphocyte Ratio, Neutrophil–Lymphocyte Ratio and Monocyte–Lymphocyte Ratio in Head and Neck Cancers: A Detailed PRISMA Compliant Systematic Review and Meta-Analysis”
by Kumarasamy, C.; Tiwary, V.; Sunil, K.; Suresh, D.; Shetty, S.; Muthukaliannan, G. K.; Baxi, S. and Jayaraj, R.
Cancers 2021, 13(16), 4166; https://doi.org/10.3390/cancers13164166
Available online: https://www.mdpi.com/2072-6694/13/16/4166

3. “Margin Assessment in Soft Tissue Sarcomas: Review of the Literature”
by Sambri, A.; Caldari, E.; Fiore, M.; Zucchini, R.; Giannini, C.; Pirini, M. G.; Spinnato, P.; Cappelli, A.; Donati, D. M. and De Paolis, M.
Cancers 2021, 13(7), 1687; https://doi.org/10.3390/cancers13071687
Available online: https://www.mdpi.com/2072-6694/13/7/1687

4. “Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review”
by Foerster, R.; Zwahlen, D. R.; Buchali, A.; Tang, H.; Schroeder, C.; Windisch, P.; Vu, E.; Akbaba, S.; Bostel, T.; Sprave, T.; Zamboglou, C.; Zilli, T.; Stelmes, J.-J.; Telkhade, T. and Murthy, V.  
Cancers 2021, 13(4), 759; https://doi.org/10.3390/cancers13040759
Available online: https://www.mdpi.com/2072-6694/13/4/759

5. “The Effects of Multidisciplinary Team Meetings on Clinical Practice for Colorectal, Lung, Prostate and Breast Cancer: A Systematic Review”
by Kočo, L.; Weekenstroo, H. H. A.; Lambregts, D. M. J.; Sedelaar, J. P. M.; Prokop, M.; Fütterer, J. J. and Mann, R. M.
Cancers 2021, 13(16), 4159; https://doi.org/10.3390/cancers13164159
Available online: https://www.mdpi.com/2072-6694/13/16/4159

6. “A Systematic Review of the Safety, Feasibility and Benefits of Exercise for Patients with Advanced Cancer”
by De Lazzari, N.; Niels, T.; Tewes, M. and Götte, M.
Cancers 2021, 13(17), 4478; https://doi.org/10.3390/cancers13174478
Available online: https://www.mdpi.com/2072-6694/13/17/4478

7. “Obesity as a Risk Factor for Prostate Cancer Mortality: A Systematic Review and Dose-Response Meta-Analysis of 280,199 Patients”
by Rivera-Izquierdo, M.; Pérez de Rojas, J.; Martínez-Ruiz, V.; Pérez-Gómez, B.; Sánchez, M.-J.; Khan, K. S. and Jiménez-Moleón, J. J.
Cancers 2021, 13(16), 4169; https://doi.org/10.3390/cancers13164169
Available online: https://www.mdpi.com/2072-6694/13/16/4169

8. “Radiomics Models for Predicting Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Radiomics Quality Score Assessment”
by Wang, Q.; Li, C.; Zhang, J.; Hu, X.; Fan, Y.; Ma, K.; Sparrelid, E. and Brismar, T. B.
Cancers 2021, 13(22), 5864; https://doi.org/10.3390/cancers13225864
Available online: https://www.mdpi.com/2072-6694/13/22/5864

9. “Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis”
by Horeweg, N.; Mittal, P.; Gradowska, P. L.; Boere, I.; Chopra, S. and Nout, R. A.
Cancers 2021, 13(8), 1880; https://doi.org/10.3390/cancers13081880
Available online: https://www.mdpi.com/2072-6694/13/8/1880

10. “Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies”
by Zahnreich, S. and Schmidberger, H.
Cancers 2021, 13(11), 2607; https://doi.org/10.3390/cancers13112607
Available online: https://www.mdpi.com/2072-6694/13/11/2607

1. “Novel Transfer Learning Approach for Medical Imaging with Limited Labeled Data”
by Alzubaidi, L.; Al-Amidie, M.; Al-Asadi, A.; Humaidi, A. J.; Al-Shamma, O.; Fadhel, M. A.; Zhang, J. L.; Santamaria, J. and Duan, Y.
Cancers 2021, 13(7), 1590; https://doi.org/10.3390/cancers13071590
Available online: https://www.mdpi.com/2072-6694/13/7/1590 

2. “Transfer Learning in Breast Cancer Diagnoses via Ultrasound Imaging”
by Ayana, G.; Dese, K. and Choe, S. W.
Cancers 2021, 13(4), 738; https://doi.org/10.3390/cancers13040738
Available online: https://www.mdpi.com/2072-6694/13/4/738

3. “Structured Reporting of Rectal Cancer Staging and Restaging: A Consensus Proposal”
by Granata, V.; Caruso, D.; Grassi, R.; Cappabianca, S.; Reginelli, A.; Rizzati, R.; Masselli, G.; Golfieri, R.; Rengo, M.; Regge, D.; Lo Re, G.; Pradella, S.; Fusco, R.; Faggioni, L.; Laghi, A.; Miele, V.; Neri, E. and Coppola, F.
Cancers 2021, 13(9), 2135; https://doi.org/10.3390/cancers13092135
Available online: https://www.mdpi.com/2072-6694/13/9/2135

4. “Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions”
by Lawlor, R. T.; Mattiolo, P.; Mafficini, A.; Hong, S.-M.; Piredda, M. L.; Taormina, S. V.; Malleo, G.; Marchegiani, G.; Pea, A.; Salvia, R.; Kryklyva, V.; Shin, J. I.; Brosens, L. A.; Milella, M.; Scarpa, A. and Luchini, C.
Cancers 2021, 13(13), 3119; https://doi.org/10.3390/cancers13133119
Available online: https://www.mdpi.com/2072-6694/13/13/3119

5. “OmiEmbed: A Unified Multi-Task Deep Learning Framework for Multi-Omics Data”
by Zhang, X.; Xing, Y.; Sun, K. and Guo, Y.
Cancers 2021, 13(12), 3047; https://doi.org/10.3390/cancers13123047
Available online: https://www.mdpi.com/2072-6694/13/12/3047

6. “Identification of Cancer Hub Gene Signatures Associated with Immune-Suppressive Tumor Microenvironment and Ovatodiolide as a Potential Cancer Immunotherapeutic Agent”
by Chen, J.-H.; Wu, A. T. H.; Lawal, B.; Tzeng, D. T. W.; Lee, J.-C.; Ho, C.-L. and Chao, T.-Y.
Cancers 2021, 13(15), 3847; https://doi.org/10.3390/cancers13153847
Available online: https://www.mdpi.com/2072-6694/13/15/3847

7. “Nanopore Sequencing Reveals Global Transcriptome Signatures of Mitochondrial and Ribosomal Gene Expressions in Various Human Cancer Stem-like Cell Populations”
by Witte, K. E.; Hertel, O.; Windmöller, B. A.; Helweg, L. P.; Höving, A. L.; Knabbe, C.; Busche, T.; Greiner, J. F. W.; Kalinowski, J.; Noll, T.; Mertzlufft, F.; Beshay, M.; Pfitzenmaier, J.; Kaltschmidt, B.; Kaltschmidt, C.; Banz-Jansen, C. and Simon, M.
Cancers 2021, 13(5), 1136; https://doi.org/10.3390/cancers13051136
Available online: https://www.mdpi.com/2072-6694/13/5/1136

8. “Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia”
by Vial, J. P.; Lechevalier, N.; Lacombe, F.; Dumas, P.-Y.; Bidet, A.; Leguay, T.; Vergez, F.; Pigneux, A. and Béné, M.C.
Cancers 2021, 13(4), 629; https://doi.org/10.3390/cancers13040629
Available online: https://www.mdpi.com/2072-6694/13/4/629

9. “Homology-Based Image Processing for Automatic Classification of Histopathological Images of Lung Tissue”
by Nishio, M.; Nishio, M.; Jimbo, N. and Nakane, K.
Cancers 2021, 13(6), 1192; https://doi.org/10.3390/cancers13061192
Available online: https://www.mdpi.com/2072-6694/13/6/1192

10. “Convolutional Neural Network-Based Clinical Predictors of Oral Dysplasia: Class Activation Map Analysis of Deep Learning Results”
by Camalan, S.; Mahmood, H.; Binol, H.; Araújo, A. L. D.; Santos-Silva, A. R.; Vargas, P. A.; Lopes, M. A.; Khurram, S. A. and Gurcan, M. N.
Cancers 2021, 13(6), 1291; https://doi.org/10.3390/cancers13061291
Available online: https://www.mdpi.com/2072-6694/13/6/1291

1. “Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis”
by Luo, D.; Wang, X.; Burda, C. and Basilion, J. P.
Cancers 2021, 13(8), 1825; https://doi.org/10.3390/cancers13081825
Available online: https://www.mdpi.com/2072-6694/13/8/1825

2. “Radiomics-Derived Data by Contrast Enhanced Magnetic Resonance in RAS Mutations Detection in Colorectal Liver Metastases”
by Granata, V.; Fusco, R.; Avallone, A.; De Stefano, A.; Ottaiano, A.; Sbordone, C.; Brunese, L.; Izzo, F. and Petrillo, A.
Cancers 2021, 13(3), 453; https://doi.org/10.3390/cancers13030453
Available online: https://www.mdpi.com/2072-6694/13/3/453

3. “DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges”
by Sabir, F.; Zeeshan, M.; Laraib, U.; Barani, M.; Rahdar, A.; Cucchiarini, M. and Pandey, S.
Cancers 2021, 13(14), 3396; https://doi.org/10.3390/cancers13143396
Available online: https://www.mdpi.com/2072-6694/13/14/3396

4. “Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer”
by Hildebrand, L. A.; Pierce, C. J.; Dennis, M.; Paracha, M. and Maoz, A.
Cancers 2021, 13(3), 391; https://doi.org/10.3390/cancers13030391
Available online: https://www.mdpi.com/2072-6694/13/3/391

5. “Diagnostic Utility of the Immunohistochemical Expression of Serine and Arginine Rich Splicing Factor 1 (SRSF1) in the Differential Diagnosis of Adult Gliomas”
by Broggi, G.; Salvatorelli, L.; Barbagallo, D.; Certo, F.; Altieri, R.; Tirrò, E.; Massimino, M.; Vigneri, P.; Guadagno, E.; Maugeri, G.; D’Agata, V.; Musumeci, G.; Ragusa, M.; Barbagallo, G. M. V.; Russo, D. and Caltabiano, R.
Cancers 2021, 13(9), 2086; https://doi.org/10.3390/cancers13092086
Available online: https://www.mdpi.com/2072-6694/13/9/2086

6. “Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells”
by Dixon, K. J.; Wu, J. and Walcheck, B.
Cancers 2021, 13(2), 312; https://doi.org/10.3390/cancers13020312
Available online: https://www.mdpi.com/2072-6694/13/2/312

7. “Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study”
by Fanizzi, A.; Pomarico, D.; Paradiso, A.; Bove, S.; Diotaiuti, S.; Didonna, V.; Giotta, F.; La Forgia, D.; Latorre, A.; Pastena, M. I.; Tamborra, P.; Zito, A.; Lorusso, V. and Massafra, R.
Cancers 2021, 13(2), 352; https://doi.org/10.3390/cancers13020352
Available online: https://www.mdpi.com/2072-6694/13/2/352

8. “The Frontal Aslant Tract and Supplementary Motor Area Syndrome: Moving towards a Connectomic Initiation Axis”
by Briggs, R. G.; Allan, P. G.; Poologaindran, A.; Dadario, N. B.; Young, I. M.; Ahsan, S. A.; Teo, C. and Sughrue, M. E.
Cancers 2021, 13(5), 1116; https://doi.org/10.3390/cancers13051116
Available online: https://www.mdpi.com/2072-6694/13/5/1116

9. “Current Intraoperative Imaging Techniques to Improve Surgical Resection of Laryngeal Cancer: A Systematic Review”
by Lauwerends, L. J.; Galema, H. A.; Hardillo, J. A. U.; Sewnaik, A.; Monserez, D.; van Driel, P. B. A. A.; Verhoef, C.; Baatenburg de Jong, R. J.; Hilling, D. E. and Keereweer, S.
Cancers 2021, 13(8), 1895; https://doi.org/10.3390/cancers13081895
Available online: https://www.mdpi.com/2072-6694/13/8/1895

10. “CT Body Composition of Sarcopenia and Sarcopenic Obesity: Predictors of Postoperative Complications and Survival in Patients with Locally Advanced Esophageal Adenocarcinoma”
by Fehrenbach, U.; Wuensch, T.; Gabriel, P.; Segger, L.; Yamaguchi, T.; Auer, T. A.; Beetz, N. L.; Denecke, C.; Kröll, D.; Raakow, J.; Knitter, S.; Chopra, S.; Thuss-Patience, P.; Pratschke, J.; Hamm, B.; Biebl, M. and Geisel, D.
Cancers 2021, 13(12), 2921; https://doi.org/10.3390/cancers13122921
Available online: https://www.mdpi.com/2072-6694/13/12/2921

1. “Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy”
by Aboelella, N. S.; Brandle, C.; Kim, T.; Ding, Z.-C. and Zhou, G.
Cancers 2021, 13(5), 986; https://doi.org/10.3390/cancers13050986
Available online: https://www.mdpi.com/2072-6694/13/5/986

2. “The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression”
by García-Ortiz, A.; Rodríguez-García, Y.; Encinas, J.; Maroto-Martín, E.; Castellano, E.; Teixidó, J. and Martínez-López, J.
Cancers 2021, 13(2), 217; https://doi.org/10.3390/cancers13020217
Available online: https://www.mdpi.com/2072-6694/13/2/217

3. “The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer”
by Ribatti, D.; Solimando, A. G. and Pezzella, F.
Cancers 2021, 13(14), 3433; https://doi.org/10.3390/cancers13143433
Available online: https://www.mdpi.com/2072-6694/13/14/3433

4. “The Role of Hypoxia in Glioblastoma Radiotherapy Resistance”
by Chédeville, A. L. and Madureira, P. A.
Cancers 2021, 13(3), 542; https://doi.org/10.3390/cancers13030542
Available online: https://www.mdpi.com/2072-6694/13/3/542

5. “Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis”
by Datta, A.; Deng, S.; Gopal, V.; Yap, K. C.-H.; Halim, C. E.; Lye, M. L.; Ong, M. S.; Tan, T. Z.; Sethi, G.; Hooi, S. C.; Kumar, A. P. and Yap, C. T.
Cancers 2021, 13(8), 1882; https://doi.org/10.3390/cancers13081882
Available online: https://www.mdpi.com/2072-6694/13/8/1882

6. “Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma”
by Hanamura, I.
Cancers 2021, 13(2), 256; https://doi.org/10.3390/cancers13020256
Available online: https://www.mdpi.com/2072-6694/13/2/256

7. “Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy”
by Bharadwaj, A. G.; Holloway, R. W.; Miller, V. A. and Waisman, D. M.
Cancers 2021, 13(8), 1838; https://doi.org/10.3390/cancers13081838
Available online: https://www.mdpi.com/2072-6694/13/8/1838

8. “Collagen Type XI Alpha 1 (COL11A1): A Novel Biomarker and a Key Player in Cancer”
by Nallanthighal, S.; Heiserman, J. P. and Cheon, D.-J.
Cancers 2021, 13(5), 935; https://doi.org/10.3390/cancers13050935
Available online: https://www.mdpi.com/2072-6694/13/5/935

9. “Cancer-Associated Fibroblast-Induced Resistance to Chemotherapy and Radiotherapy in Gastrointestinal Cancers”
by Ham, I.-H.; Lee, D. and Hur, H.
Cancers 2021, 13(5), 1172; https://doi.org/10.3390/cancers13051172
Available online: https://www.mdpi.com/2072-6694/13/5/1172

10. “Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer”
by Zahra, F. T.; Sajib, M. S. and Mikelis, C. M.
Cancers 2021, 13(6), 1422; https://doi.org/10.3390/cancers13061422
Available online: https://www.mdpi.com/2072-6694/13/6/1422

1. “PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols”
by Crosta, S.; Boldorini, R.; Bono, F.; Brambilla, V.; Dainese, E.; Fusco, N.; Gianatti, A.; L’Imperio, V.; Morbini, P. and Pagni, F.
Cancers 2021, 13(2), 292; https://doi.org/10.3390/cancers13020292
Available online: https://www.mdpi.com/2072-6694/13/2/292

2. “Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology”
by Becker, A. P.; Sells, B. E.; Haque, S. J. and Chakravarti, A.
Cancers 2021, 13(4), 761; https://doi.org/10.3390/cancers13040761
Available online: https://www.mdpi.com/2072-6694/13/4/761

3. “Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases”
by Hu, Z.; Pan, Z.; Chen, W.; Shi, Y.; Wang, W.; Yuan, J.; Wang, E.; Zhang, S.; Kurt, H.; Mai, B.; Zhang, X.; Liu, H.; Rios, A. A.; Ma, H. Y.; Nguyen, N. D.; Medeiros, L. J. and Hu, S.
Cancers 2021, 13(4), 878; https://doi.org/10.3390/cancers13040878
Available online: https://www.mdpi.com/2072-6694/13/4/878

4. “Long, Noncoding RNA Dysregulation in Glioblastoma”
by DeSouza, P. A.; Qu, X.; Chen, H.; Patel, B.; Maher, C. A. and Kim, A. H.
Cancers 2021, 13(7), 1604; https://doi.org/10.3390/cancers13071604
Available online: https://www.mdpi.com/2072-6694/13/7/1604

5. “Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response”
by Rickard, B. P.; Conrad, C.; Sorrin, A. J.; Ruhi, M. K.; Reader, J. C.; Huang, S. A.; Franco, W.; Scarcelli, G.; Polacheck, W. J.; Roque, D. M.; del Carmen, M. G.; Huang, H.-C.; Demirci, U. and Rizvi, I.
Cancers 2021, 13(17), 4318; https://doi.org/10.3390/cancers13174318
Available online: https://www.mdpi.com/2072-6694/13/17/4318

6. “RalGPS2 Interacts with Akt and PDK1 Promoting Tunneling Nanotubes Formation in Bladder Cancer and Kidney Cells Microenvironment”
by D’Aloia, A.; Arrigoni, E.; Costa, B.; Berruti, G.; Martegani, E.; Sacco, E. and Ceriani, M.
Cancers 2021, 13(24), 6330; https://doi.org/10.3390/cancers13246330
Available online: https://www.mdpi.com/2072-6694/13/24/6330

7. “Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors”
by Singh, R.; Fazal, Z.; Freemantle, S. J. and Spinella, M. J.
Cancers 2021, 13(7), 1506; https://doi.org/10.3390/cancers13071506
Available online: https://www.mdpi.com/2072-6694/13/7/1506

8. “Activation of the S100A7/RAGE Pathway by IGF-1 Contributes to Angiogenesis in Breast Cancer”
by Muoio, M. G.; Talia, M.; Lappano, R.; Sims, A. H.; Vella, V.; Cirillo, F.; Manzella, L.; Giuliano, M.; Maggiolini, M.; Belfiore, A. and De Francesco, E. M.
Cancers 2021, 13(4), 621; https://doi.org/10.3390/cancers13040621
Available online: https://www.mdpi.com/2072-6694/13/4/621

9. “Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma”
by Peiseler, M. and Tacke, F.
Cancers 2021, 13(4), 730; https://doi.org/10.3390/cancers13040730
Available online: https://www.mdpi.com/2072-6694/13/4/730

10. “Radio-Iodide Treatment: From Molecular Aspects to the Clinical View”
by De la Vieja, A. and Riesco-Eizaguirre, G.
Cancers 2021, 13(5), 995; https://doi.org/10.3390/cancers13050995
Available online: https://www.mdpi.com/2072-6694/13/5/995

1. “Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer”
by Lopez-Beltran, A.; Cimadamore, A.; Blanca, A.; Massari, F.; Vau, N.; Scarpelli, M.; Cheng, L. and Montironi, R.
Cancers 2021, 13(1), 131; https://doi.org/10.3390/cancers13010131
Available online: https://www.mdpi.com/2072-6694/13/1/131

2. “IL-12 Family Cytokines in Cancer and Immunotherapy”
by Mirlekar, B. and Pylayeva-Gupta, Y.
Cancers 2021, 13(2), 167; https://doi.org/10.3390/cancers13020167
Available online: https://www.mdpi.com/2072-6694/13/2/167

3. “STING Agonists as Cancer Therapeutics”
by Amouzegar, A.; Chelvanambi, M.; Filderman, J. N.; Storkus, W. J. and Luke, J. J.
Cancers 2021, 13(11), 2695; https://doi.org/10.3390/cancers13112695
Available online: https://www.mdpi.com/2072-6694/13/11/2695

4. “Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma”
by Ferrucci, P. F.; Pala, L.; Conforti, F. and Cocorocchio, E.
Cancers 2021, 13(6), 1383; https://doi.org/10.3390/cancers13061383
Available online: https://www.mdpi.com/2072-6694/13/6/1383

5. “Senolytics for Cancer Therapy: Is All that Glitters Really Gold?”
by Carpenter, V. J.; Saleh, T. and Gewirtz, D. A.
Cancers 2021, 13(4), 723; https://doi.org/10.3390/cancers13040723
Available online: https://www.mdpi.com/2072-6694/13/4/723

6. “CTLA-4 in Regulatory T Cells for Cancer Immunotherapy”
by Sobhani, N.; Tardiel-Cyril, D. R.; Davtyan, A.; Generali, D.; Roudi, R. and Li, Y.
Cancers 2021, 13(6), 1440; https://doi.org/10.3390/cancers13061440
Available online: https://www.mdpi.com/2072-6694/13/6/1440

7. “The Role of Macrophages in Cancer Development and Therapy”
by Cendrowicz, E.; Sas, Z.; Bremer, E. and Rygiel, T. P.
Cancers 2021, 13(8), 1946; https://doi.org/10.3390/cancers13081946
Available online: https://www.mdpi.com/2072-6694/13/8/1946

8. “The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment”
by Haist, M.; Stege, H.; Grabbe, S.; Bros, M.
Cancers 2021, 13(2), 210; https://doi.org/10.3390/cancers13020210
Available online: https://www.mdpi.com/2072-6694/13/2/210

9. “Immune Resistance in Lung Adenocarcinoma”
by Spella, M. and Stathopoulos, G. T.
Cancers 2021, 13(3), 384; https://doi.org/10.3390/cancers13030384
Available online: https://www.mdpi.com/2072-6694/13/3/384

10. “Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases”
by Bailly, C.; Thuru, X. and Quesnel, B.
Cancers 2021, 13(12), 3034; https://doi.org/10.3390/cancers13123034
Available online: https://www.mdpi.com/2072-6694/13/12/3034

Conference: 2022 BMES Annual Meeting
Date: 12–15 October 2022
Place: San Antonio, Texas, USA
Booth: #346

MDPI will be attending the 2022 BMES Annual Meeting as an exhibitor from 12 to 15 October 2022 in San Antonio, Texas, USA.

BMES holds an annual meeting where they have hosted up to 5,500 biomedical engineers who attend more than 2,500 scientific presentations on cancer treatment, heart disease, women’s health, global health disparities, and more. The meeting allows members to advocate for their innovative solutions, demonstrating their commitment to the society’s core value of health equity for all individuals. In addition, BMES shares scientific information to inspire the up-and-coming generation through four scientific journals, three special interest groups, and collaborations with other scientific societies to elevate the visibility and significant impact that the biomedical engineering community has worldwide as the thought leaders behind the future of human health.

From 12 to 15 October 2022, in the vibrant multicultural city of San Antonio, we will celebrate the tremendous contributions made by BMES members in research, teaching, education, and the workforce that directly impact many sectors of our society. We also aim to highlight equity issues in healthcare and education, stemming from racial and socioeconomic diversity, gender and sexual orientation, and disabilities.

The following MDPI journals will be represented:

• Applied Sciences;
• Bioengineering;
• Biomedicines;
• Biomimetics;
• Biomolecules;
• Biosensors;
• Cancers;
• CIMB;
• Diseases.

Please do not hesitate to reach out if you plan on attending this conference. Our delegates look forward to meeting you in person and answering any questions that you might have.

Peer Review Week began 19 September 2022 under the theme of “Research Integrity: Creating and Supporting Trust in Research”. Through various blog articles, podcast, and webinar, we discussed this crucial subject throughout the week, celebrating the essential role peer review plays in maintaining research quality.

To begin, we held a Webinar on the topic. Professor Peter W. Choate and Dr. Emmanuel Obeng-Gyasi joined Dr. Ioana Craciun, one of MDPI’s scientific officers, for an in-depth discussion.

We invite you to view the event recording:

During the week, the MDPI Blog in a series articles highlighted how good Peer Review safeguards research integrity. The following topics were covered:

• Peer Review Week 2022
• Research Integrity
• What We’ve Learned About Peer Review Reports
• 4 Steps to the Perfect Peer Review Report
• How to Write the Perfect Peer Review Report: An Interview
• Inviting Great Peer Reviewers

In a new edition of Insight Faster, an MDPI podcast, we were delighted to talk to the co-chairs of the Peer Review Week committee, Jayashree Rajagopalan (Senior Manager of Global Community Engagement for CACTUS) and Danielle Padula (Head of Marketing and Community Development at Scholastica) to get their take on this year’s event and its related topics.

You can find the Podcast here.

We hope you enjoy the contents!

1. “Magnetic Nanoparticles—A Multifunctional Potential Agent for Diagnosis and Therapy”
by Chouhan, R. S.; Horvat, M.; Ahmed, J.; Alhokbany, N.; Alshehri, S. M. and Gandhi, S.
Cancers 2021, 13(9), 2213; https://doi.org/10.3390/cancers13092213
Available online: https://www.mdpi.com/2072-6694/13/9/2213 

2. “A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy”
by Andleeb, A.; Andleeb, A.; Asghar, S.; Zaman, G.; Tariq, M.; Mehmood, A.; Nadeem, M.; Hano, C.; Lorenzo, J. M. and Abbasi, B. H.
Cancers 2021, 13(11), 2818; https://doi.org/10.3390/cancers13112818
Available online: https://www.mdpi.com/2072-6694/13/11/2818

3. “Quercetin and Its Nano-Scale Delivery Systems in Prostate Cancer Therapy: Paving the Way for Cancer Elimination and Reversing Chemoresistance”
by Hussain, Y.; Mirzaei, S.; Ashrafizadeh, M.; Zarrabi, A.; Hushmandi, K.; Khan, H. and Daglia, M.
Cancers 2021, 13(7), 1602; https://doi.org/10.3390/cancers13071602
Available online: https://www.mdpi.com/2072-6694/13/7/1602

4. “Prediction of Microvascular Invasion in Hepatocellular Carcinoma via Deep Learning: A Multi-Center and Prospective Validation Study”
by Wei, J.; Jiang, H.; Zeng, M.; Wang, M.; Niu, M.; Gu, D.; Chong, H.; Zhang, Y.; Fu, F.; Zhou, M. et al.
Cancers 2021, 13(10), 2368; https://doi.org/10.3390/cancers13102368
Available online: https://www.mdpi.com/2072-6694/13/10/2368

5. “Radiogenomics: Hunting Down Liver Metastasis in Colorectal Cancer Patients”
by de la Pinta, C.; Castillo, M. E.; Collado, M.; Galindo-Pumariño, C. and Peña, C.
Cancers 2021, 13(21), 5547; https://doi.org/10.3390/cancers13215547
Available online: https://www.mdpi.com/2072-6694/13/21/5547

6. “Breast Tumor Characterization Using [¹⁸F]FDG-PET/CT Imaging Combined with Data Preprocessing and Radiomics”
by Krajnc, D.; Papp, L.; Nakuz, T. S.; Magometschnigg, H. F.; Grahovac, M.; Spielvogel, C. P.; Ecsedi, B.; Bago-Horvath, Z.; Haug, A.; Karanikas, G. et al.
Cancers 2021, 13(6), 1249; https://doi.org/10.3390/cancers13061249
Available online: https://www.mdpi.com/2072-6694/13/6/1249

7. “Molecular Changes in Retinoblastoma beyond RB1: Findings from Next-Generation Sequencing”
by Francis, J. H.; Richards, A. L.; Mandelker, D. L.; Berger, M. F.; Walsh, M. F.; Dunkel, I. J.; Donoghue, M. T. A. and Abramson, D. H.
Cancers 2021, 13(1), 149; https://doi.org/10.3390/cancers13010149
Available online: https://www.mdpi.com/2072-6694/13/1/149

8. “Use of PET Imaging in Neuro-Oncological Surgery”
by Holzgreve, A.; Albert, N. L.; Galldiks, N. and Suchorska, B.
Cancers 2021, 13(9), 2093; https://doi.org/10.3390/cancers13092093
Available online: https://www.mdpi.com/2072-6694/13/9/2093

9. “Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies”
by Randrian, V.; Evrard, C. and Tougeron, D.
Cancers 2021, 13(12), 3063; https://doi.org/10.3390/cancers13123063
Available online: https://www.mdpi.com/2072-6694/13/12/3063

10. “Validation of a Point-of-Care Optical Coherence Tomography Device with Machine Learning Algorithm for Detection of Oral Potentially Malignant and Malignant Lesions”
by James, B. L.; Sunny, S. P.; Heidari, A. E.; Ramanjinappa, R. D.; Lam, T.; Tran, A. V.; Kankanala, S.; Sil, S.; Tiwari, V.; Patrick, S. et al.
Cancers 2021, 13(14), 3583; https://doi.org/10.3390/cancers13143583
Available online: https://www.mdpi.com/2072-6694/13/14/3583

1. “Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives”
by Hafezi, S. and Rahmani, M.
Cancers 2021, 13(6), 1292; https://doi.org/10.3390/cancers13061292
Available online: https://www.mdpi.com/2072-6694/13/6/1292

2. “Stimuli-Responsive Hydrogels for Cancer Treatment: The Role of pH, Light, Ionic Strength and Magnetic Field”
by Andrade, F.; Roca-Melendres, M. M.; Durán-Lara, E. F.; Rafael, D. and Schwartz, S., Jr.
Cancers 2021, 13(5), 1164; https://doi.org/10.3390/cancers13051164
Available online: https://www.mdpi.com/2072-6694/13/5/1164

3. “The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review”
by Rascio, F.; Spadaccino, F.; Rocchetti, M. T.; Castellano, G.; Stallone, G.; Netti, G. S. and Ranieri, E.
Cancers 2021, 13(16), 3949; https://doi.org/10.3390/cancers13163949
Available online: https://www.mdpi.com/2072-6694/13/16/3949

4. “Perspectives on the Role of Isoliquiritigenin in Cancer”
by Wang, K.-L.; Yu, Y.-C. and Hsia, S.-M.
Cancers 2021, 13(1), 115; https://doi.org/10.3390/cancers13010115
Available online: https://www.mdpi.com/2072-6694/13/1/115

5. “The Role of p53 Signaling in Colorectal Cancer”
by Liebl, M. C. and Hofmann, T. G.
Cancers 2021, 13(9), 2125; https://doi.org/10.3390/cancers13092125
Available online: https://www.mdpi.com/2072-6694/13/9/2125

6. “MicroRNA Therapeutics in Cancer: Current Advances and Challenges”
by Reda El Sayed, S.; Cristante, J.; Guyon, L.; Denis, J.; Chabre, O. and Cherradi, N.
Cancers 2021, 13(11), 2680; https://doi.org/10.3390/cancers13112680
Available online: https://www.mdpi.com/2072-6694/13/11/2680

7. “Glucose Transporters as a Target for Anticancer Therapy”
by Pliszka, M. and Szablewski, L.
Cancers 2021, 13(16), 4184; https://doi.org/10.3390/cancers13164184
Available online: https://www.mdpi.com/2072-6694/13/16/4184

8. “The Exciting New Field of HER2-Low Breast Cancer Treatment”
by Eiger, D.; Agostinetto, E.; Saúde-Conde, R. and de Azambuja, E.
Cancers 2021, 13(5), 1015; https://doi.org/10.3390/cancers13051015
Available online: https://www.mdpi.com/2072-6694/13/5/1015

9. “Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy”
by Kato, T.; Wakiyama, H.; Furusawa, A.; Choyke, P. L. and Kobayashi, H.
Cancers 2021, 13(11), 2535; https://doi.org/10.3390/cancers13112535
Available online: https://www.mdpi.com/2072-6694/13/11/2535

10. “Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours”
by Setargew, Y. F. I.; Wyllie, K.; Grant, R. D.; Chitty, J. L. and Cox, T. R.
Cancers 2021, 13(3), 491; https://doi.org/10.3390/cancers13030491
Available online: https://www.mdpi.com/2072-6694/13/3/491

MDPI will be attending the 34th Annual Conference of the International Society for Environmental Epidemiology (ISEE 2022), held in Athens, Greece, from 18 to 21 September 2022. The main theme of the 2022 conference is “Strengthening the global role of environmental epidemiology”, stressing the need to study and understand local conditions in order to synthesize knowledge and make a difference for our planet. In the 2022 conference we will continue advancing our society’s aims in promoting epidemiological studies that link environmental exposures to human health.

During this conference, MDPI (at booth #22) will welcome researchers from different backgrounds to visit and share their latest inspirations with us.

The following MDPI journals will be represented:

• IJERPH (leading journal);
• Sustainability;
• Healthcare;
• Children;
• Cancers;
• Climate;
• Environments;
• Earth;
• Societies;
• Epidemiologia.

If you plan on attending this conference, feel free to stop by our booth: #22. Our delegates look forward to meeting you in person to answer any questions that you may have.

For more information about the conference, please see the following link: https://isee2022.org/.

1 . “Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany”
by Jacob, L.; Loosen, S. H.; Kalder, M.; Luedde, T.; Roderburg, C.; Kostev, K.
Cancers 2021, 13(3), 408; https://doi.org/10.3390/cancers13030408
Available online: https://www.mdpi.com/2072-6694/13/3/408

2. “A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer”
by Yasin, H. K.; Taylor, A. H.; Ayakannu, T.
Cancers 2021, 13(9), 2149; https://doi.org/10.3390/cancers13092149
Available online: https://www.mdpi.com/2072-6694/13/9/2149

3. “Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies”
by Lorini, L.; Bescós Atín, C.; Thavaraj, S.; Müller-Richter, U.; Alberola Ferranti, M.; Pamias Romero, J.; Sáez Barba, M.; de Pablo García-Cuenca, A.; Braña García, I.; Bossi, P. et al.
Cancers 2021, 13(15), 3696; https://doi.org/10.3390/cancers13153696
Available online: https://www.mdpi.com/2072-6694/13/15/3696

4. “Fucoxanthin and Colorectal Cancer Prevention”
by Terasaki, M.; Kubota, A.; Kojima, H.; Maeda, H.; Miyashita, K.; Kawagoe, C.; Mutoh, M.; Tanaka, T.
Cancers 2021, 13(10), 2379; https://doi.org/10.3390/cancers13102379
Available online: https://www.mdpi.com/2072-6694/13/10/2379

5. “Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study”
by Lee, J.; Park, S.-S.; Kim, T. Y.; Lee, D.-G.; Kim, D.-W.
Cancers 2021, 13(3), 471; https://doi.org/10.3390/cancers13030471
Available online: https://www.mdpi.com/2072-6694/13/3/471

6. “Mycobiome and Cancer: What Is the Evidence?”
by Lee, J.; Park, S.-S.; Kim, T.Y.; Lee, D.-G.; Kim, D.-W.
Cancers 2021, 13(13), 3149; https://doi.org/10.3390/cancers13133149
Available online: https://www.mdpi.com/2072-6694/13/13/3149

7. “Comparison of Cancer Patients to Non-Cancer Patients among COVID-19 Inpatients at a National Level”
by Bernard, A.; Cottenet, J.; Bonniaud, P.; Piroth, L.; Arveux, P.; Tubert-Bitter, P.; Quantin, C.
Cancers 2021, 13(6), 1436; https://doi.org/10.3390/cancers13061436
Available online: https://www.mdpi.com/2072-6694/13/6/1436

8. “Towards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive Review”
by Ferrari, A.; Neefs, I.; Hoeck, S.; Peeters, M.; Van Hal, G.
Cancers 2021, 13(8), 1820; https://doi.org/10.3390/cancers13081820
Available online: https://www.mdpi.com/2072-6694/13/8/1820

9. “Renal Cell Carcinoma Health Disparities in Stage and Mortality among American Indians/Alaska Natives and Hispanic Americans: Comparison of National Cancer Database and Arizona Cancer Registry Data”
by Valencia, C. I.; Asmar, S.; Hsu, C.-H.; Gachupin, F. C.; Wong, A. C.; Chipollini, J.; Lee, B. R.; Batai, K.
Cancers 2021, 13(5), 990; https://doi.org/10.3390/cancers13050990
Available online: https://www.mdpi.com/2072-6694/13/5/990

10. “Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients”
by Valencia, C. I.; Asmar, S.; Hsu, C.-H.; Gachupin, F. C.; Wong, A. C.; Chipollini, J.; Lee, B. R.; Batai, K. et al.
Cancers 2021, 13(17), 4312; https://doi.org/10.3390/cancers13174312
Available online: https://www.mdpi.com/2072-6694/13/17/4312

1. “The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia”
by Lühmann, J. L.; Stelter, M.; Wolter, M.; Kater, J.; Lentes, J.; Bergmann, A. K.; Schieck, M.; Göhring, G.; Möricke, A.; Cario, G. et al.
Cancers 2021, 13(17), 4388; https://doi.org/10.3390/cancers13174388
Available online: https://www.mdpi.com/2072-6694/13/17/4388

2. “The Microbiome in Childhood Acute Lymphoblastic Leukemia”
by Oldenburg, M.; Rüchel, N.; Janssen, S.; Borkhardt, A.; Gössling, K. L.
Cancers 2021, 13(19), 4947; https://doi.org/10.3390/cancers13194947
Available online: https://www.mdpi.com/2072-6694/13/19/4947

3. “Plasticity in Neuroblastoma Cell Identity Defines a Noradrenergic-to-Mesenchymal Transition (NMT)”
by Gautier, M.; Thirant, C.; Delattre, O.; Janoueix-Lerosey, I.
Cancers 2021, 13(12), 2904; https://doi.org/10.3390/cancers13122904
Available online: https://www.mdpi.com/2072-6694/13/12/2904
 
4. “Pediatric Mixed-Phenotype Acute Leukemia: What’s New?”
by Batra, S.; Ross, A. J.
Cancers 2021, 13(18), 4658; https://doi.org/10.3390/cancers13184658
Available online: https://www.mdpi.com/2072-6694/13/18/4658
 
5. “Preliminary Radiogenomic Evidence for the Prediction of Metastasis and Chemotherapy Response in Pediatric Patients with Osteosarcoma Using 18F-FDG PET/CT, EZRIN, and KI67”
by Kim, B.-C.; Kim, J.; Kim, K.; Byun, B. H.; Lim, I.; Kong, C.-B.; Song, W. S.; Koh, J.-S.; Woo, S.-K.
Cancers 2021, 13(11), 2671; https://doi.org/10.3390/cancers13112671
Available online: https://www.mdpi.com/2072-6694/13/11/2671
 
6. “Unbalance in Iron Metabolism in Childhood Leukemia Converges with Treatment Intensity: Biochemical and Clinical Analysis”
by Łęcka, M.; Słomka, A.; Albrecht, K.; Żekanowska, E.; Romiszewski, M.; Styczyński, J.
Cancers 2021, 13(12), 3029; https://doi.org/10.3390/cancers13123029
Available online: https://www.mdpi.com/2072-6694/13/12/3029
 
7. “Natural History of Untreated Retinoblastoma”
by Zhao, J.; Feng, Z.; Gallie, B. L.
Cancers 2021, 13(15), 3646; https://doi.org/10.3390/cancers13153646
Available online: https://www.mdpi.com/2072-6694/13/15/3646
 
8. “Advances in the First Line Treatment of Pediatric Acute Myeloid Leukemia in the Polish Pediatric Leukemia and Lymphoma Study Group from 1983 to 2019”
by Czogała, M.; Balwierz, W.; Pawińska-Wąsikowska, K.; Książek, T.; Bukowska-Strakova, K.; Czogała, W.; Sikorska-Fic, B.; Matysiak, M.; Skalska-Sadowska, J.; Wachowiak, J. et al.
Cancers 2021, 13(18), 4536; https://doi.org/10.3390/cancers13184536
Available online: https://www.mdpi.com/2072-6694/13/18/4536
 
9. “Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved Diagnostics”
by Chouvarine, P.; Antić, Ž.; Lentes, J.; Schröder, C.; Alten, J.; Brüggemann, M.; Carrillo-de Santa Pau, E.; Illig, T.; Laguna, T.; Schewe, D. et al.
Cancers 2021, 13(22), 5653; https://doi.org/10.3390/cancers13225653
Available online: https://www.mdpi.com/2072-6694/13/22/5653
 
10. “Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma”
by Nasarre, P.; Garcia, D. I.; Siegel, J. B.; Bonilla, I. V.; Mukherjee, R.; Hilliard, E.; Chakraborty, P.; Nasarre, C.; Yustein, J. T.; Lang, M. et al.
Cancers 2021, 13(11), 2696; https://doi.org/10.3390/cancers13112696
Available online: https://www.mdpi.com/2072-6694/13/11/2696

MDPI will be attending the 2022 CAGPO ACMOO Annual Conference, hosted by the 2022 CAGPO Annual Conference Committee, which will be held from 15 to 18 September 2022 in Toronto, Canada.

The CAGPO mission statement is to unify general practitioners in oncology, promote communication amongst general practitioners in oncology in tertiary care and primary care settings, act and speak as the recognized authority on behalf of and for the benefit of general practitioners in oncology and their interests, and promote the role of general practitioners in oncology within cancer centers and within the primary care setting. The conference is to address the learning needs of general practitioners in oncology (GPOs) and oncology-allied health attendees. During this meeting, we will address recent advancements in the standards of oncology care. Our speakers include GPOs, medical and radiation oncologists, as well as speakers from the disciplines of family medicine and clinical trials.

The following MDPI journals will be represented:

• Current Oncology (leading);
• Cancers;
• Medical Sciences;
• Pharmacy;
• Journal of Clinical Medicine;
• Cells;
• Onco.

If you are attending this conference, please feel free to start an on-site conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have.

For more information about the conference, please visit the following link: http://cagpo-annual-conference.ca, or contact the Current Oncology Editorial Office at [email protected].

MDPI will be attending ASHG 2022, held in Los Angeles, USA, from 25 to 29 October 2022.

The following MDPI journals will be represented:

• Genes;
• JPM;
• Biomedicines;
• Biomolecules;
• Cardiogenetics;
• Cancers;
• Brain Science;
• Symmetry;
• Diagnostics;
• Metabolites;
• Cells;
• Biology;
• Humans;
• DNA.

If you plan on attending this conference, feel free to stop by our booth: #1844. Our delegates look forward to meeting you in person to answer any questions you may have.

For more information about the conference, please see the following link:

https://www.ashg.org/meetings/2022-annual-meeting/.

1. “Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries”
by Huang, J.; Koulaouzidis, A.; Marlicz, W.; Lok, V.; Chu, C.; Ngai, C. H.; Zhang, L.; Chen, P.; Wang, S.; Yuan, J.; et al.
Cancers 2021, 13(1), 141; https://doi.org/10.3390/cancers13010141
Available online: https://www.mdpi.com/2072-6694/13/1/141

2. “A Review of Circulating Tumour Cell Enrichment Technologies”
by Rushton, A. J.; Nteliopoulos, G.; Shaw, J. A.; Coombes, R. C.
Cancers 2021, 13(5), 970; https://doi.org/10.3390/cancers13050970
Available online: https://www.mdpi.com/2072-6694/13/5/970

3. “Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy”
by Koustoulidou, S.; Hoorens, M. W. H.; Dalm, S. U.; Mahajan, S.; Debets, R.; Seimbille, Y.; de Jong, M.
Cancers 2021, 13(5), 1100; https://doi.org/10.3390/cancers13051100
Available online: https://www.mdpi.com/2072-6694/13/5/1100

4. “Home-Based Aerobic and Resistance Exercise Interventions in Cancer Patients and Survivors: A Systematic Review”
by Batalik, L.; Winnige, P.; Dosbaba, F.; Vlazna, D.; Janikova, A.
Cancers 2021, 13(8), 1915; https://doi.org/10.3390/cancers13081915
Available online: https://www.mdpi.com/2072-6694/13/8/1915

5. “Exploring the Potential Role of the Gut Microbiome in Chemotherapy-Induced Neurocognitive Disorders and Cardiovascular Toxicity”
by Ciernikova, S.; Mego, M.; Chovanec, M.
Cancers 2021, 13(4), 782; https://doi.org/10.3390/cancers13040782
Available online: https://www.mdpi.com/2072-6694/13/4/782

6. “Fatigue in Cancer Patients in Palliative Care—A Review on Pharmacological Interventions”
by Klasson, C.; Helde Frankling, M.; Lundh Hagelin, C.; Björkhem-Bergman, L.
Cancers 2021, 13(5), 985; https://doi.org/10.3390/cancers13050985
Available online: https://www.mdpi.com/2072-6694/13/5/985

7. “Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data”
by Hansen, T. F.; Qvortrup, C.; Pfeiffer, P.
Cancers 2021, 13(5), 1031; https://doi.org/10.3390/cancers13051031
Available online: https://www.mdpi.com/2072-6694/13/5/1031

8. “Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview”
by Janssen, S. H. M.; van der Graaf, W. T. A.; van der Meer, D. J.; Manten-Horst, E.; Husson, O.
Cancers 2021, 13(19), 4847; https://doi.org/10.3390/cancers13194847
Available online: https://www.mdpi.com/2072-6694/13/19/4847

9. “Comparative Evaluation of Novel ¹⁷⁷Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting”
by Tano, H.; Oroujeni, M.; Vorobyeva, A.; Westerlund, K.; Liu, Y.; Xu, T.; Vasconcelos, D.; Orlova, A.; Karlström, A. E.; Tolmachev, V.
Cancers 2021, 13(3), 500; https://doi.org/10.3390/cancers13030500
Available online: https://www.mdpi.com/2072-6694/13/3/500

10. “Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy”
by Li, Y.; Lustberg, M. B.; Hu, S.
Cancers 2021, 13(4), 766; https://doi.org/10.3390/cancers13040766
Available online: https://www.mdpi.com/2072-6694/13/4/766

1. “Trends in Research on Exosomes in Cancer Progression and Anticancer Therapy”
by Sinha, D.; Roy, S.; Saha, P.; Chatterjee, N.; Bishayee, A.
Cancers 2021, 13(2), 326; https://doi.org/10.3390/cancers13020326
Available online: https://www.mdpi.com/2072-6694/13/2/326

2. “Mechanisms of Resistance to KRASG12C Inhibitors”
by Dunnett-Kane, V.; Nicola, P.; Blackhall, F.; Lindsay, C.
Cancers 2021, 13(1), 151; https://doi.org/10.3390/cancers13010151
Available online: https://www.mdpi.com/2072-6694/13/1/151

3. “Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter”
by Hompland, T.; Fjeldbo, C. S.; Lyng, H.
Cancers 2021, 13(3), 499; https://doi.org/10.3390/cancers13030499
Available online: https://www.mdpi.com/2072-6694/13/3/499

4. “Circular RNAs: Emerging Regulators of the Major Signaling Pathways Involved in Cancer Progression”
by Papatsirou, M.; Artemaki, P. I.; Karousi, P.; Scorilas, A.; Kontos, C. K.
Cancers 2021, 13(11), 2744; https://doi.org/10.3390/cancers13112744
Available online: https://www.mdpi.com/2072-6694/13/11/2744

5. “Targeting CDK9 for Anti-Cancer Therapeutics”
by Mandal, R.; Becker, S.; Strebhardt, K.
Cancers 2021, 13(9), 2181; https://doi.org/10.3390/cancers13092181
Available online: https://www.mdpi.com/2072-6694/13/9/2181

6. “EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance”
by Uribe, M. L.; Marrocco, I.; Yarden, Y.
Cancers 2021, 13(11), 2748; https://doi.org/10.3390/cancers13112748
Available online: https://www.mdpi.com/2072-6694/13/11/2748

7. “The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma”
by Ou A.; Ott M.; Fang D.; Heimberger A. B.
Cancers 2021, 13(3), 437; https://doi.org/10.3390/cancers13030437
Available online: https://www.mdpi.com/2072-6694/13/3/437

8. “Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer”
by Domen, A.; Quatannens, D.; Zanivan, S.; Deben, C.; Van Audenaerde, J.; Smits, E.; Wouters, A.; Lardon, F.; Roeyen, G.; Verhoeven, Y.; Janssens, A.; Vandamme, T.; van Dam, P.; Peeters, M.; Prenen, H. 
Cancers 2021, 13(5), 987; https://doi.org/10.3390/cancers13050987
Available online: https://www.mdpi.com/2072-6694/13/5/987

9. “Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies”
by Hattinger, C. M.; Patrizio, M. P.; Fantoni, L.; Casotti, C.; Riganti, C.; Serra, M.
Cancers 2021, 13(12), 2878; https://doi.org/10.3390/cancers13122878
Available online: https://www.mdpi.com/2072-6694/13/12/2878

10. “Hypoxia-Induced Cancer Cell Responses Driving Radioresistance of Hypoxic Tumors: Approaches to Targeting and Radiosensitizing”
by Kabakov, A. E.; Yakimova, A. O. 
Cancers 2021, 13(5), 1102; https://doi.org/10.3390/cancers13051102
Available online: https://www.mdpi.com/2072-6694/13/5/1102

Cancers (ISSN: 2072-6694) will be attending ESMO 2022, held in Paris, France, from 9 to 13 September 2022. The European Society for Medical Oncology (ESMO) conference is the most important annual event with the greatest impact on cancer research, open to scholars and specialists from academia and the medical profession. During this conference, MDPI (at booth #P231) will welcome researchers from different backgrounds to visit and share their latest inspirations with us.

The following MDPI journals will be represented:

• Cancers (leading journal);
• Cells;
• Current Oncology;
• Biomedicines;
• Diagnostics;
• Future Pharmacology;
• IJMS;
• Onco;
• Pharmaceutics.

If you plan on attending this conference, feel free to stop by our booth #P231. Our delegates look forward to meeting you in person to answer any questions you may have.

For more information about the conference, please see the following link: https://www.esmo.org/.

1. “Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study”
by Banys-Paluchowski, M.; Gasparri, M. L.; de Boniface, J.; Gentilini, O.; Stickeler, E.; Hartmann, S.; Thill, M.; Rubio, I. T.; Di Micco, R.; Bonci, E.-A.; et al.
Cancers 2021, 13(7), 1565; https://doi.org/10.3390/Cancers13071565
Available online: https://www.mdpi.com/2072-6694/13/7/1565 

2. “Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials”
by Rochigneux, P.; Chanez, B.; De Rauglaudre, B.; Mitry, E.; Chabannon, C.; Gilabert, M.
Cancers 2021, 13(2), 271; https://doi.org/10.3390/Cancers13020271
Available online: https://www.mdpi.com/2072-6694/13/2/271

3. “Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations”
by Lee, P. C.; Hendifar, A.; Osipov, A.; Cho, M.; Li, D.; Gong, J.
Cancers 2021, 13(7), 1706; https://doi.org/10.3390/Cancers13071706
Available online: https://www.mdpi.com/2072-6694/13/7/1706

4. “The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials”
by Hervieu, C.; Christou, N.; Battu, S.; Mathonnet, M.
Cancers 2021, 13(5), 1092; https://doi.org/10.3390/Cancers13051092
Available online: https://www.mdpi.com/2072-6694/13/5/1092

5. “N-3 Long-Chain Polyunsaturated Fatty Acids, Eicosapentaenoic and Docosahexaenoic Acid, and the Role of Supplementation during Cancer Treatment: A Scoping Review of Current Clinical Evidence”
by Newell, M.; Mazurak, V.; Postovit, L. M.; Field, C. J.
Cancers 2021, 13(6), 1206; https://doi.org/10.3390/Cancers13061206
Available online: https://www.mdpi.com/2072-6694/13/6/1206

6. “Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance”
by Wang, S.-H.; Yeh, S.-H.; Chen, P.-J.
Cancers 2021, 13(10), 2454; https://doi.org/10.3390/Cancers13102454
Available online: https://www.mdpi.com/2072-6694/13/10/2454

7. “The Effects of High-Intensity Interval Training vs. Moderate-Intensity Continuous Training on Inflammatory Markers, Body Composition, and Physical Fitness in Overweight/Obese Survivors of Breast Cancer: A Randomized Controlled Clinical Trial”
by Hooshmand Moghadam, B.; Golestani, F.; Bagheri, R.; Cheraghloo, N.; Eskandari, M.; Wong, A.; Nordvall, M.; Suzuki, K.; Pournemati, P.
Cancers 2021, 13(17), 4386; https://doi.org/10.3390/Cancers13174386
Available online: https://www.mdpi.com/2072-6694/13/17/4386

8. “Interstitial Photodynamic Therapy for Glioblastomas: A Standardized Procedure for Clinical Use”
by Leroy, H.-A.; Baert, G.; Guerin, L.; Delhem, N.; Mordon, S.; Reyns, N.
Cancers 2021, 13(22), 5754; https://doi.org/10.3390/Cancers13225754
Available online: https://www.mdpi.com/2072-6694/13/22/5754

9. “Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications”
by van Harten, A. M.; Brakenhoff, R. H.
Cancers 2021, 13(11), 2774; https://doi.org/10.3390/Cancers13112774
Available online: https://www.mdpi.com/2072-6694/13/11/2774

10. “Could Photodynamic Therapy Be a Promising Therapeutic Modality in Hepatocellular Carcinoma Patients? A Critical Review of Experimental and Clinical Studies”
by Kumar, A.; Moralès, O.; Mordon, S.; Delhem, N.
Cancers 2021, 13(20), 5176; https://doi.org/10.3390/Cancers13205176
Available online: https://www.mdpi.com/2072-6694/13/20/5176

1. “Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?”
by Victoria Heredia-Soto; Nuria Rodríguez-Salas; Jaime Feliu
Cancers 2021, 13(8), 1986; https://doi.org/10.3390/cancers13081986
Available online: https://www.mdpi.com/2072-6694/13/8/1986

2. “New Molecular Mechanisms and Clinical Impact of circRNAs in Human Cancer”
by Giulia Fontemaggi; Chiara Turco; Gabriella Esposito; Silvia Di Agostino
Cancers 2021, 13(13), 3154; https://doi.org/10.3390/cancers13133154
Available online: https://www.mdpi.com/2072-6694/13/13/3154

3. “Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer”
by Matthew G. Davey; Sean O. Hynes; Michael J. Kerin; Nicola Miller; Aoife J. Lowery
Cancers 2021, 13(17), 4455; https://doi.org/10.3390/cancers13174455
Available online: https://www.mdpi.com/2072-6694/13/17/4455

4. “Functional Interaction among lncRNA HOTAIR and MicroRNAs in Cancer and Other Human Diseases”
by Monica Cantile; Maurizio Di Bonito; Maura Tracey De Bellis; Gerardo Botti
Cancers 2021, 13(3), 570; https://doi.org/10.3390/cancers13030570
Available online: https://www.mdpi.com/2072-6694/13/3/570

5. “Resistance to Molecularly Targeted Therapies in Melanoma”
by Meet Patel; Adam Eckburg; Shahina Gantiwala; Zachary Hart; Joshua Dein; Katie Lam; Neelu Puri
Cancers 2021, 13(5), 1115; https://doi.org/10.3390/cancers13051115
Available online: https://www.mdpi.com/2072-6694/13/5/1115

6. “Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease”
by Gian Paolo Caviglia; Angelo Armandi; Chiara Rosso; Silvia Gaia; Serena Aneli; Emanuela Rolle; Maria Lorena Abate; Antonella Olivero; Aurora Nicolosi; Marta Guariglia; Davide Giuseppe Ribaldone; Patrizia Carucci; Giorgio Maria Saracco; Elisabetta Bugianesi
Cancers 2021, 13(10), 2305; https://doi.org/10.3390/cancers13102305
Available online: https://www.mdpi.com/2072-6694/13/10/2305

7. “Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)”
by Pauline Gilson; Jean-Louis Merlin; Alexandre Harlé
Cancers 2021, 13(7), 1491; https://doi.org/10.3390/cancers13071491
Available online: https://www.mdpi.com/2072-6694/13/7/1491

8. “Urine as a Source of Liquid Biopsy for Cancer”
by Masanori Oshi; Vijayashree Murthy; Hideo Takahashi; Michelle Huyser; Maiko Okano; Yoshihisa Tokumaru; Omar M. Rashid; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Cancers 2021, 13(11), 2652; https://doi.org/10.3390/cancers13112652
Available online: https://www.mdpi.com/2072-6694/13/11/2652

9. “Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer—A Comprehensive Review”
by Greta Brezgyte; Vinay Shah; Daria Jach; Tatjana Crnogorac-Jurcevic
Cancers 2021, 13(11), 2722; https://doi.org/10.3390/cancers13112722
Available online: https://www.mdpi.com/2072-6694/13/11/2722

10. “Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies”
by Cora Palanca-Ballester; Aitor Rodriguez-Casanova; Susana Torres; Silvia Calabuig-Fariñas; Francisco Exposito; Diego Serrano; Esther Redin; Karmele Valencia; Eloisa Jantus-Lewintre; Angel Diaz-Lagares; Luis Montuenga; Juan Sandoval; Alfonso Calvo
Cancers 2021, 13(12), 3016; https://doi.org/10.3390/cancers13123016
Available online: https://www.mdpi.com/2072-6694/13/12/3016

Vaccines help the body fight disease and therefore immunization is a key component of primary health care and is a development success story that saves millions of lives every year. They work to protect the body from viruses (e.g., human papillomavirus, hepatitis B virus) or boost the body's immune system to fight cancer.

August is National Immunization Awareness Month, and we would like to share some of the high-quality and innovative research findings published in Cancers (ISSN: 2072-6694).

The list of relevant papers can be seen below:

“Plasma-Activated Medium Potentiates the Immunogenicity of Tumor Cell Lysates for Dendritic Cell-Based Cancer Vaccines”
by Tomić, S.; Petrović, A.; Puač, N.; Škoro, N.; Bekić, M.; Petrović, Z. L.; Čolić, M.
Cancers 2021, 13(7), 1626; https://doi.org/10.3390/cancers13071626
Available online: https://www.mdpi.com/2072-6694/13/7/1626

“COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience”
by So, A. C. P.; McGrath, H.; Ting, J.; Srikandarajah, K.; Germanou, S.; Moss, C.; Russell, B.; Monroy-Iglesias, M.; Dolly, S.; Irshad, S.; Van Hemelrijck, M.; Enting, D.
Cancers 2021, 13(14), 3573; https://doi.org/10.3390/cancers13143573
Available online: https://www.mdpi.com/2072-6694/13/14/3573

“Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs”
by Agbarya, A.; Sarel, I.; Ziv-Baran, T.; Agranat, S.; Schwartz, O.; Shai, A.; Nordheimer, S.; Fenig, S.; Shechtman, Y.; Kozlener, E.; Taha, T.; Nasrallah, H.; Parikh, R.; Elkoshi, N.; Levy, C.; Khoury, R.; Brenner, R.
Cancers 2021, 13(16), 4191; https://doi.org/10.3390/cancers13164191
Available online: https://www.mdpi.com/2072-6694/13/16/4191

“Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy”
by Horn, L. A.; Fousek, K.; Hamilton, D. H.; Hodge, J. W.; Zebala, J. A.; Maeda, D. Y.; Schlom, J.; Palena, C.
Cancers 2021, 13(5), 968; https://doi.org/10.3390/cancers13050968
Available online: https://www.mdpi.com/2072-6694/13/5/968

“Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment”
by Ghandili, S.; Schönlein, M.; Lütgehetmann, M.; Schulze zur Wiesch, J.; Becher, H.; Bokemeyer, C.; Sinn, M.; Weisel, K. C.; Leypoldt, L. B.
Cancers 2021, 13(15), 3800; https://doi.org/10.3390/cancers13153800
Available online: https://www.mdpi.com/2072-6694/13/15/3800

“Antigenic Essence: Upgrade of Cellular Cancer Vaccines”
by Lokhov, P. G.; Balashova, E. E.
Cancers 2021, 13(4), 774; https://doi.org/10.3390/cancers13040774
Available online: https://www.mdpi.com/2072-6694/13/4/774

“Vaccine-Based Immunotherapy for Head and Neck Cancers”
by Beyaert, S.; Machiels, J. -P.; Schmitz, S.
Cancers 2021, 13(23), 6041; https://doi.org/10.3390/cancers13236041
Available online: https://www.mdpi.com/2072-6694/13/23/6041

“Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization”
by Przybyla, A.; Lehmann, A. A.; Zhang, T.; Mackiewicz, J.; Galus, Ł.; Kirchenbaum, G. A.; Mackiewicz, A.; Lehmann, P. V.
Cancers 2021, 13(2), 223; https://doi.org/10.3390/cancers13020223
Available online: https://www.mdpi.com/2072-6694/13/2/223

“Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study”
by Jørgensen, N. G.; Kaae, J.; Grauslund, J. H.; Met, Ö.; Nielsen, S. L.; Pedersen, A. W.; Svane, I. M.; Ehrnrooth, E.; Andersen, M. H.; Zachariae, C.; Skov, L.
Cancers 2021, 13(4), 911; https://doi.org/10.3390/cancers13040911
Available online: https://www.mdpi.com/2072-6694/13/4/911

“Novel Protein-Based Vaccine against Self-Antigen Reduces the Formation of Sporadic Colon Adenomas in Mice”
by Belnoue, E.; Leystra, A. A.; Carboni, S.; Cooper, H. S.; Macedo, R. T.; Harvey, K. N.; Colby, K. B.; Campbell, K. S.; Vanderveer, L. A.; Clapper, M. L.; Derouazi, M.
Cancers 2021, 13(4), 845; https://doi.org/10.3390/cancers13040845
Available online: https://www.mdpi.com/2072-6694/13/4/845

You are welcome to submit relevant papers to the journal Section “Cancer Immunology and Immunotherapy” at https://www.mdpi.com/journal/cancers/sections/Cancer_Immunology_Immunotherapy.

Dr. Subbaya Subramanian
Associate Section Editor-in-Chief of Cancers

Sarcomas are malignant tumors that commonly arise from bone and soft tissue such as muscle, fat, and nerves. Bone sarcomas include osteosarcoma, chondrosarcoma, and Ewing’s sarcoma, and soft-tissue sarcomas include liposarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, synovial sarcoma, leiomyosarcoma, and rhabdomyosarcoma. The characteristics of sarcoma are its rarity (low frequency of occurrence) and diversity (various histological types). The frequency of sarcoma is extremely low compared to carcinomas such as lung cancer and colon cancer, and sarcomas account for only 1% of all malignant tumors.

Due to the rarity and variety of sarcoma, it is difficult to diagnose and treat the disease appropriately. In addition, many patients are referred to cancer centers after receiving unplanned excision.

July has been designated as “Sarcoma Awareness Month”, with the yellow ribbon as a symbol, and various activities have been carried out so far to raise awareness of this rare cancer for research support and development in treatment all over the world.

We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to highlight multiple research projects in this field, covering mechanisms in the tumor microenvironment, early detection, promising therapeutic targets, and new therapeutic strategies. We hope this announcement will provide useful information for clinical practice.

The list of relevant papers can be seen below:

• “Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?”
  by Anne Gomez-Brouchet et al.
  Available online: https://www.mdpi.com/2072-6694/13/3/423

• “Exploring Metabolic Adaptations to the Acidic Microenvironment of Osteosarcoma Cells Unveils Sphingosine 1-Phosphate as a Valuable Therapeutic Target”
  by Margherita Cortini et al.
  Available online: https://www.mdpi.com/2072-6694/13/2/311

• “Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies”
  by Claudia Maria Hattinger et al.
  Available online: https://www.mdpi.com/2072-6694/13/12/2878

• “Chondrosarcoma-from Molecular Pathology to Novel Therapies”
  by Agnieszka E. Zając et al.
  Available online: https://www.mdpi.com/2072-6694/13/10/2390

• “Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy”
  by Luana Madalena Sousa et al.
  Available online: https://www.mdpi.com/2072-6694/13/15/3885

You are welcome to submit relevant papers to the Special Issue “Sarcoma and Bone Cancer Awareness Month” at https://www.mdpi.com/si/cancers/IQ9P79398L.

Dr. Shinji Miwa, Editorial Board Member of Cancers

The 2021 citation metrics have been released in the Journal Citation Reports (JCR), and we’re pleased to announce the following results for MDPI journals:

For more information on Impact Factors and what it means to index academic journals, please visit our related blog posts.

* Journals given their first Impact Factor in 2022

Source: 2021 Journal Impact Factors, Journal Citation Reports ^TM (Clarivate, 2022)

MDPI’s Young Investigator Awards recognize promising junior researchers, acknowledge their contributions, and enhance communication among scientists. We are proud to present the winners for the year 2021 in the “Medicine & Pharmacology” category. The winners were selected by the journals’ editors.

We warmly congratulate the awarded young investigators for their outstanding contributions. MDPI will continue to provide support and recognition to the academic community.

Biomedicines:

• Jasper Fuk-Woo Chan, Queen Mary Hospital, Hong Kong
• Mateusz Maciejczyk, Medical University of Bialystok, Poland

Current Oncology:

• Matteo Lambertini, University of Genova, Italy

Dentistry Journal:

• Helen Rogers, Newcastle University, UK

Healthcare:

• Amir Karami, University of South Carolina, USA

Journal of Clinical Medicine:

• Andrea Palermo, Campus Bio-Medico University, Italy

Journal of Personalized Medicine:

• Simone Di Franco, University of Palermo, Italy
• Catriona Hippman, University of Calgary, Canada

Medicina:

• Veeru Kasivisvanathan, University College London, UK
• Andrea Cortegiani, University of Palermo, Italy; University Hospital Policlinico Paolo Giaccone, Italy

Pharmaceutics:

• Qi Zhou, Purdue University, USA

We are proud to recognize the winners of MDPI’s 2021 Travel Awards in the “Medicine & Pharmacology” category for their outstanding presentations and to present them with the prize.

MDPI journals regularly offer travel awards to encourage talented junior scientists to present their latest research at academic conferences in specific fields, which helps to increase their influence.

The winners mentioned below were carefully selected by the journal editors based on an outline of their research and the work to be presented at an academic conference.

We would like to warmly congratulate the Travel Awards winners for the year 2021 and wish them the greatest success with their future research endeavors. MDPI will continue to enhance communication among scientists.

Biomedicines:

• Soheil Saeedi, University of Zurich, Switzerland

Dentistry Journal:

• Shawn Alexander Hallett, University of Michigan, USA

Medicines:

• Claire Albert, Yale University, USA

Pharmaceuticals:

• Raquel Filipa da Costa Viveiros, NOVA University of Lisbon, Portugal
• Patrick Jim Küppers, University Hospital Bonn, Germany

In order to acknowledge our reviewers, who so generously dedicate their time to reviewing papers, and demonstrate diligence, professionalism, and timeliness when reviewing manuscripts, MDPI journals regularly offer outstanding reviewer awards to scholars who participate in the peer-review process.

We are proud to recognize winners for the year 2021 in the “Medicine & Pharmacology” category for their outstanding contributions among extensive competition by presenting them with an Outstanding Reviewer Award.

We would like to take this opportunity to congratulate all of the winners on their achievement. MDPI will continue to provide support and recognition to the academic community.

Cancers:

• Antonio G. Solimando, University of Bari Aldo Moro, Italy
• Chenghui Li, University of Arkansas for Medical Sciences, USA
• Joaquim Carreras, Tokai University, Japan
• Pierfrancesco Franco, University of Turin School of Medicine, Italy
• Laurentiu Pop, University of Texas Southwestern Medical Center, USA

Current Oncology:

• Margaret Fitch, University of Toronto, Canada
• Caroline Mariano, BC Cancer Agency, Canada; University of British Columbia, Canada

Healthcare:

• Naser Alsharairi, Griffith University, Australia
• Peter W. Choate, Mount Royal University, Canada
• Qin Xiang Ng, National University of Singapore, Singapore

Journal of Clinical Medicine:

• Giulio Francesco, Sapienza University of Rome, Italy
• Sebastian Schnaubelt, Medical University of Vienna, Austria
• Olga Kislitsina, Northwestern University, Northwestern Memorial Hospital, USA

Journal of Personalized Medicine:

• Onofrio Laselva, University of Foggia, Italy
• Ping-Hsun Wu, Kaohsiung Medical University, Taiwan
• Vladimir Vladimirov, Virginia Commonwealth University, USA
• Mauro Giuffrè, University of Trieste, Italy

Medical Sciences:

• Erika Palmieri, National Cancer Institute at Frederick, USA

Tomography:

• Anjul Khadria, California Institute of Technology, Pasadena, USA

The purpose of our Best Paper Awards is to promote and recognize the most impactful contributions published within MDPI journals.

The editors of each journal carefully selected reviews and research papers through a rigorous judging process based on criteria such as the scientific merit, overall impact, and the quality of presentation of the papers published in the journal last year.

We are honored to present the winners in the “Medicine & Pharmacology” category, who were selected amongst extensive competition, and congratulate the authors for their outstanding scientific publications.

MDPI will continue to provide support and recognition to the academic community.

Antibiotics:

• “Antimicrobial and Synergistic Effects of Commercial Piperine and Piperlongumine in Combination with Conventional Antimicrobials”

by Eunice Ego Mgbeahuruike, Milla Stålnacke, Heikki Vuorela and Yvonne Holm

Antibiotics 2019, 8(2), 55; doi:10.3390/antibiotics8020055

• “Antibiotic Discovery: Where Have We Come from, Where Do We Go?”

by Bernardo Ribeiro da Cunha, Luís P. Fonseca and Cecília R. C. Calado

Antibiotics 2019, 8(2), 45; doi:10.3390/antibiotics8020045

Dentistry Journal:

• “Regeneration of the Periodontal Apparatus in Aggressive Periodontitis Patients”

by Zvi Artzi, Shiran Sudri, Ori Platner and Avital Kozlovsky

Dent. J. 2019, 7(1), 29; doi:10.3390/dj7010029

• “Treatment of Peri-Implant Mucositis with Repeated Application of Chlorhexidine Chips or Gel during Supportive Therapy—A Randomized Clinical Trial”

by Philipp Sahrmann, Cyrill Bettschart, Daniel B. Wiedemeier, Ahmed Al-Majid, Thomas Attin and Patrick R. Schmidlin

Dent. J. 2019, 7(4), 115; doi:10.3390/dj7040115

Healthcare:

• “Two-Year Use of Care Robot Zora in Dutch Nursing Homes: An Evaluation Study”

by Chantal Huisman and Helianthe Kort

Healthcare 2019, 7(1), 31; doi:10.3390/healthcare7010031

• “The Interlinked Rising Epidemic of Insufficient Sleep and Diabetes Mellitus”

by Vijay Kumar Chattu, Soosanna Kumary Chattu, Deepa Burman, David Warren Spence and Seithikurippu R. Pandi-Perumal

Healthcare 2019, 7(1), 37; doi:10.3390/healthcare7010037

Journal of Clinical Medicine:

• “Periodontitis: A Multifaceted Disease of Tooth-Supporting Tissues”

by Eija Könönen, Mervi Gursoy and Ulvi Kahraman Gursoy

Clin. Med. 2019, 8(8), 1135; doi:10.3390/jcm8081135

• “The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity”

by Yueyuan Zhou, Yusuke Yamamoto, Zhongdang Xiao and Takahiro Ochiya

Clin. Med. 2019, 8(7), 1025; doi:10.3390/jcm8071025

• “Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR”

by Tara K. Sigdel, Felipe Acosta Archila, Tudor Constantin, Sarah A. Prins, Juliane Liberto, Izabella Damm, Parhom Towfighi, Samantha Navarro, Eser Kirkizlar, Zachary P. Demko, Allison Ryan, Styrmir Sigurjonsson, Reuben D. Sarwal, Szu-Chuan Hseish, Chitranon Chan-On, Bernhard Zimmermann, Paul R. Billings, Solomon Moshkevich and Minnie M. Sarwal

Clin. Med. 2019, 8(1), 19; doi:10.3390/jcm8010019

Medicina:

• “Tumor Microenvironment”

by Borros Arneth

Medicina 2020, 56(1), 15; doi: 10.3390/medicina56010015

• “Comparative Epidemiology and Resistance Trends of Common Urinary Pathogens in a Tertiary-Care Hospital: A 10-Year Surveillance Study”

by Márió Gajdács, Marianna Ábrók, Andrea Lázár, and Katalin Burián

Medicina 2019, 55(7), 356; doi: 10.3390/medicina55070356

Pharmaceutics:

• “3D Printed Pellets (Miniprintlets): A Novel, Multi-Drug, Controlled Release Platform Technology”

by Atheer Awad, Fabrizio Fina, Sarah J. Trenfield, Pavanesh Patel, Alvaro Goyanes, Simon Gaisford and Abdul W. Basit.

Pharmaceutics 2019, 11(4), 148; doi:10.3390/pharmaceutics11040148

• “Mathematical Modeling of Release Kinetics from Supramolecular Drug Delivery Systems”

by Constantin Mircioiu, Victor Voicu, Valentina Anuta, Andra Tudose, Christian Celia, Donatella Paolino, Massimo Fresta, Roxana Sandulovici and Ion Mircioiu

Pharmaceutics 2019, 11(3), 140; doi:10.3390/pharmaceutics11030140

The 2021 citation metrics have been officially released in Scopus!

We are pleased to announce that 182 MDPI journals are included, of which:

● 21 journals received their first CiteScore.
● 85% of journals increased their CiteScore from 2020.
● 155 journals (85%) ranked above average, in at least one category.

The following 65 MDPI journals (36%) ranked among the top 25% of journals, in at least one category:

Source: 2021 CiteScores™ (Elsevier)

As May is National Cancer Research Month, we would like to take this opportunity to thank all the authors who have contributed to Cancers (ISSN: 2072-6694). In particular, we would like to highlight some of the high-quality, high-impact, and innovative research findings published in the journal in the last year, which cover multiple key research areas, including primary prevention, early detection, advanced surgical techniques, and new therapeutic strategies in cancer treatment.

As researchers continue to work tirelessly against COVID-19, several publications have also demonstrated the effectiveness of anti-SARS-CoV-2-antibody vaccination in cancer treatment. Modulating the immune system for cancer immunotherapy remains an actively investigated area. Multiple studies show the effects of immune check inhibitors in cancer treatment, and novel predictive and prognostic biomarkers for multiple cancer types, as well as novel therapeutic approaches for cancer treatment, have also been described. Finally, reviews and research articles have reported the use of spatial omics, an emerging class of high-throughput technologies, to identify novel spatially resolved cancer biomarkers. You can see the list of papers, divided into categories, below:

1. Covid and Clinical Management of Cancer Patients

2. Targeting Immune Check Point Molecules in Cancer Treatment

3. Novel Biomarkers for Cancer Diagnosis and Prognosis

4. Novel Therapeutic Approaches and Clinical Trials Associated with Cancer Treatment

5. Spatial Omics Analyses of Tumor Tissue

We hope that the scientific community will continue to support the journal in working towards disseminating high-impact research findings from researchers and thus improving the survival rates and the quality of life of cancer patients.

Prof. Dr. Samuel C. Mok, Editor-in-Chief of Cancers
Dr. Deepak Nagrath, Associate Editor-in-Chief of Cancers

We are delighted to announce that Dr. Farrukh Aqil, Assistant Professor of Medicine at the University of Louisville, has just taken over as Section Editor-in-Chief of Section “Cancer Epidemiology and Prevention” in Cancers (ISSN: 2072-6694).

Dr. Aqil attended the Aligarh Muslim University to earn his doctorate in Microbiology in 2006. He then moved to the United States to complete his post-doctoral training in the Cancer Chemoprevention and Control Program of Brown Cancer Center, Louisville. After his post-doctorate, he served as an Instructor at the Department of Medicine, University of Louisville, Louisville for two years. Along with his faculty position as an Assistant Professor at the University of Louisville, he has been meticulously involved with the James Graham Brown Cancer Center as an integral member.

Dr. Aqil has been involved in cancer prevention research for over 12 years and has received several awards, including the Faculty Excellence Award of the University of Louisville. Dr. Aqil has published over 80 articles in peer-reviewed journals, 13 book chapters, and has edited 4 books. He has participated in many conferences and presented his work as 80 abstracts/oral presentations/invited talks. He aims to keep up with his contributions to expand outreach in cancer research.

The following is a short Q&A with Dr. Farrukh Aqil, who shared his vision for the journal with us, as well as his views of the research area:

1. What appealed to you about Cancers that made you want to take the role as its Section Editor-in-Chief?
The fact that Cancers emphasizes the importance of transparency and reproducibility in research by publishing research on both clinical and basic science issues related to cancer research is what attracted me to the journal. I have been associated with this journal as an author, reviewer, and editorial board member and always found that it is the leading source of information on the issues that shape oncology. A question that often arises in cancer research is how we can make better progress in prevention and early detection. Cancers is one of those platforms that helps to move research in the right direction. The aspect that I think is the closest to my thought process is the importance the journal places on publishing results from all over the world with the same enthusiasm. Another aspect of Cancers is publishing meaningful negative results with the same interest as positive results. I feel that the negative results help research grow faster because we know what to avoid, so we move closer to positive outcomes.

2. What is your vision for Cancers?
My vision is to create a difference in the field of cancer research and open doors for new minds and provide them with a chance to put forth their research while not just confining experiments to positive and negative results; in the coming years, I would like to see this journal to be a platform for researchers to dissipate their knowledge and research outcomes. I would consider this as an opportunity to motivate and encourage researchers to communicate their research rationale, and I would make sure to add my expertise to every bit of research I go through.

3. What does the future of this field of research look like?
It is a well-known fact that the number of cancer patients has been increasing over the years; the deaths due to this disease are very much evident, and these numbers will continue to grow in the coming years. According to statistics, one-half to two-thirds of all cancer cases can be prevented upon the implementation of cancer prevention strategies. In my opinion, research and development in the field of cancer epidemiology and prevention is the need of the hour. Once the potential of this field is realized, the battle with cancer would be  half won and would eliminate lethal exposure to existing cancer therapies. As such, it is necessary to place importance on cancer epidemiology and prevention and to increase its outreach.

4. What do you think of the development of Open Access in the publishing field?
I believe that there should be no barriers between science and readers. It should be accessible to all without any restrictions. Additionally, as this research field is taking grip, it would benefit larger masses if the progress was transparent and reachable to all of the beginners in this field.

We warmly welcome Dr. Farrukh Aqil to his new role as Section Editor-in-Chief, and we look forward to his leading Cancers to many more milestones.

It is our great honor to congratulate the Editorial Board Members and Editors in MDPI's journals who have been distinguished as 2021 Highly Cited Researchers by Clarivate, according to Web of Science data. We herewith express our gratitude for the immense impact the named researchers continue to make on scientific progress and on our journals' development.

Clarivate's annual list of Highly Cited Researchers^TM identifies the most highly cited scientists for the past decade. Their impactful papers are among the top 1 per cent in the citation distribution of one or more of 22 fields analyzed in the "Essential Science Indicators", distinguishing them as hugely influential among their peers.